Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | GPR6 | P46095 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16818268 | 0.90 | GPR119 (0.65) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL23410111 | 0.87 | GPR119 (0.61) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2776116 | 0.86 | GPR119 (0.69) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15565981 | 0.85 | GPR119 (0.60) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15567098 | 0.85 | GPR119 (0.67) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL27151216 | 0.85 | GPR119 (0.47) | GPR119PDE4DPDE4B | |
| SCHEMBL27151214 | 0.85 | GPR119 (0.47) | GPR119PDE4DPDE4B | |
| SCHEMBL13718678 | 0.84 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17008808 | 0.84 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5971305 | 0.84 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105230-B1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-04-07 | — | — | EP | disclosed |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | Taketa Pharmaceutical Company Limited (JP) | 2019-01-15 | — | — | US | disclosed |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-3105230-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123505-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR119 17/4885PDE4D 859/4885PDE4B 803/4885 |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR119 17/4885PDE4D 859/4885PDE4B 803/4885 |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR119 16/4885PDE4D 898/4885PDE4B 866/4885 |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR119 16/4885PDE4D 898/4885PDE4B 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.